Results 191 to 200 of about 571,422 (359)

Recent Applications of Mesoporous Silica Nanoparticles in Gene Therapy

open access: yesAdvanced Healthcare Materials, EarlyView.
The review summarizes the synthesis of mesoporous silica nanoparticles (MSNs) with modifiable surface properties, functionalization strategies, mechanism of therapeutic payload release, and current applications in gene therapy, focusing on their capabilities in the targeted delivery of therapeutic nucleic acids, CRISPR‐Cas systems, and other genetic ...
Tamanna Binte Huq   +4 more
wiley   +1 more source

Fluid Shear‐Controlled Pro/Anti‐Inflammatory Osteomodulatory Construct for Drug‐Free Immune Activation Through Cationic Ion Channel Activation

open access: yesAdvanced Healthcare Materials, EarlyView.
A 3D‐printed PCL scaffold coated with Arginine was laminated with electrospun polyvinyl alcohol (PVA) nanofibers containing cationic cellulose nanocrystals (PVA@cCNC). This created nanoisland‐like regions of aligned and random cCNC‐rich fibers. The composite scaffold, under fluid shear stimulation, modulated macrophage polarization from M1 to M2 ...
Keya Ganguly   +8 more
wiley   +1 more source

Genome editing of BmFib-H gene provides an empty Bombyx mori silk gland for a highly efficient bioreactor [PDF]

open access: gold, 2014
Sanyuan Ma   +9 more
openalex   +1 more source

Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision

open access: yesAdvanced Healthcare Materials, EarlyView.
Advancements in ART improve HIV‐1 patient outcomes but are unable to eliminate latent viral DNA. To address this, CXCR4‐targeted lipid nanoparticles (T‐LNPs) for delivering CRISPR‐Cas9 to excise HIV‐1 DNA in infected cells are developed. These T‐LNPs achieve ≈60% HIV‐1 DNA excision efficacy in blood and splenic tissue, demonstrating promise for ...
Sudipta Panja   +6 more
wiley   +1 more source

Directed evolution expands CRISPR-Cas12a genome-editing capacity. [PDF]

open access: yesNucleic Acids Res
Ma E   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy